Harmony Biosciences Holdings, Inc.(HRMY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

HRMY Harmony Biosciences Holdings, Inc.

Trading 11-15 13:14:37 EST

33.05

+0.05

+0.15%

High33.51	Low32.55	Vol284.41K
Open32.95	D1 Closing33.00	Amplitude2.91%
Mkt Cap1.88B	Tradable Cap1.46B	Total Shares57.03M
T/O9.36M	T/O Rate0.65%	Tradable Shares44.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"HRMY","market":"US","secType":"STK","nameCN":"Harmony Biosciences Holdings, Inc.","latestPrice":33.05,"timestamp":1731694475010,"preClose":33,"halted":0,"volume":284406,"delay":0,"floatShares":44055610,"shares":57031297,"eps":2.105627,"marketStatus":"Trading","change":0.05,"latestTime":"11-15 13:14:37 EST","open":32.95,"high":33.51,"low":32.55,"amount":9360929.698602,"amplitude":0.029091,"askPrice":33.13,"askSize":2,"bidPrice":33.05,"bidSize":99,"shortable":3,"etf":0,"ttmEps":2.105627,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1731704400000},"marketStatusCode":2,"adr":0,"listingDate":1597809600000,"exchange":"NASDAQ","adjPreClose":33,"preHourTrading":{"tag":"盘前","latestPrice":32.94,"preClose":33,"latestTime":"09:27 EST","volume":118,"amount":3883.519948,"timestamp":1731680870020},"postHourTrading":{"tag":"盘后","latestPrice":33,"preClose":33,"latestTime":"19:51 EST","volume":11066,"amount":365200.6,"timestamp":1731631875120},"volumeRatio":0.743066,"impliedVol":0.4028,"impliedVolPercentile":0.0119},"requestUrl":"/m/hq/s/HRMY/wiki","defaultTab":"wiki","newsList":[{"id":"2481571261","title":"There May Be Some Bright Spots In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2481571261","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481571261?lang=en_us&edition=fundamental","pubTime":"2024-11-05 18:53","pubTimestamp":1730804002,"startTime":"0","endTime":"0","summary":"The most recent earnings report from Harmony Biosciences Holdings, Inc.  was disappointing for shareholders. However, our analysis suggests that the soft headline numbers are getting counterbalanced by some positive underlying factors.View our latest analysis for Harmony Biosciences Holdings. Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. That is not intended to imply we should worry about a positive accrual ratio, but it's worth noting where the accrual ratio is rather high. That's because some academic studies have suggested that high accruals ratios tend to lead to lower profit or less profit growth.This note has only looked at a single factor that sheds light on the nature of Harmony Biosciences Holdings' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a g","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/may-bright-spots-harmony-biosciences-105322581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ",".IXIC","HRMY"],"gpt_icon":1},{"id":"2481543891","title":"Harmony Biosciences Holdings: Strong Growth Potential and Attractive Valuation Amidst Robust Product Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2481543891","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481543891?lang=en_us&edition=fundamental","pubTime":"2024-11-05 13:57","pubTimestamp":1730786262,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on HRMY stock, giving a Buy rating on October 30. Graig Suvannavejh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/harmony-biosciences-holdings-strong-growth-potential-and-attractive-valuation-amidst-robust-product-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/harmony-biosciences-holdings-strong-growth-potential-and-attractive-valuation-amidst-robust-product-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HRMY"],"gpt_icon":0},{"id":"1121087399","title":"Stock Track | Harmony Biosciences Surges 6% After Earnings Beat, Value Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1121087399","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121087399?lang=en_us&edition=fundamental","pubTime":"2024-11-01 23:46","pubTimestamp":1730476001,"startTime":"0","endTime":"0","summary":"Shares of Harmony Biosciences Holdings, Inc.  soared 6.01% on Thursday, November 1st, following the release of the company's latest quarterly results and renewed interest from value investors.In its earnings report, Harmony Biosciences reported a profit of $0.79 per share, surpassing analyst estimates by 19%. While revenues of $186 million were in line with expectations, the earnings beat was seen as a positive surprise by the market. However, analysts slightly trimmed their earnings per share f","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Harmony Biosciences Surges 6% After Earnings Beat, Value Outlook","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["HRMY"],"gpt_icon":0},{"id":"2480835287","title":"Earnings Beat: Harmony Biosciences Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2480835287","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480835287?lang=en_us&edition=fundamental","pubTime":"2024-11-01 23:14","pubTimestamp":1730474097,"startTime":"0","endTime":"0","summary":"Shareholders might have noticed that Harmony Biosciences Holdings, Inc.  filed its quarterly result this time last week. The early response was not positive, with shares down 6.9% to US$32.13 in the past week. It looks like a credible result overall - although revenues of US$186m were in line with what the analysts predicted, Harmony Biosciences Holdings surprised by delivering a statutory profit of US$0.79 per share, a notable 19% above expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest  post-earnings forecasts for next year.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/earnings-beat-harmony-biosciences-holdings-151457942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HRMY"],"gpt_icon":0},{"id":"2480352828","title":"Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2480352828","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480352828?lang=en_us&edition=fundamental","pubTime":"2024-11-01 21:40","pubTimestamp":1730468415,"startTime":"0","endTime":"0","summary":"Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the \"Value\" category. Stocks with high Zacks Ranks and \"A\" grades for Value will be some of the highest-quality value stocks on the market today.One company to watch right now is Harmony Biosciences . HRMY is currently ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZVGBNd2_.kAicju5mLde7g--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZVGBNd2_.kAicju5mLde7g--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investors-undervaluing-harmony-biosciences-hrmy-134015831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ISBC","HRMY","BK4211"],"gpt_icon":0},{"id":"2480079051","title":"HRMY vs. REGN: Which Stock Is the Better Value Option?","url":"https://stock-news.laohu8.com/highlight/detail?id=2480079051","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480079051?lang=en_us&edition=fundamental","pubTime":"2024-10-31 23:40","pubTimestamp":1730389208,"startTime":"0","endTime":"0","summary":"Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc.  and Regeneron . But which of these two stocks is more attractive to value investors?We'll need to take a closer look to find out.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.Harmony Biosciences Holdings, Inc. and Regeneron are sporting Zacks Ranks of #2  and #3 , respectively, right now. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that HRMY is likely seeing its earnings outlook improve to a greater extent. But this is only part of the picture for value investors.To rea","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ksLAzii1aL14haHFbPC1Rg--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ksLAzii1aL14haHFbPC1Rg--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hrmy-vs-regn-stock-better-154008123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1974910355.USD","LU0889565916.HKD","BK4007","LU0114720955.EUR","LU0109394709.USD","BK4585","LU0058720904.USD","LU2468319806.SGD","LU2362541273.HKD","HRMY","LU0289739699.SGD","LU0320765992.SGD","LU1917777945.USD","LU2106854487.HKD","LU2023250504.SGD","LU0053666078.USD","REGN","LU2362540622.SGD","BK4139","LU0823416689.USD","LU2362541513.USD","BK4588","LU0882574055.USD","LU2089984988.USD"],"gpt_icon":0},{"id":"2480052799","title":"Harmony Biosciences Holdings, Inc. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2480052799","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480052799?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:33","pubTimestamp":1730377985,"startTime":"0","endTime":"0","summary":"Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) came out with its quarterly results last week, and we wanted to see...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrmy/harmony-biosciences-holdings/news/harmony-biosciences-holdings-inc-just-recorded-a-19-eps-beat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HRMY"],"gpt_icon":0},{"id":"2479808928","title":"Harmony Biosciences Holdings Third Quarter 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2479808928","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479808928?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:28","pubTimestamp":1730377729,"startTime":"0","endTime":"0","summary":"NasdaqGM:HRMY Earnings and Revenue Growth October 31st 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 1.1%. Earnings per share  also surpassed analyst estimates by 19%.Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in the US.The company's share price is broadly unchanged from a week ago.It is worth noting though that we have found 1 warning sign for Harmony Biosciences Holdings that you need to take into consideration.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/harmony-biosciences-holdings-third-quarter-122849315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HRMY"],"gpt_icon":0},{"id":"2479711391","title":"Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2479711391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479711391?lang=en_us&edition=fundamental","pubTime":"2024-10-31 10:30","pubTimestamp":1730341802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUABY2DWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","HRMY"],"gpt_icon":0},{"id":"2479753661","title":"BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Shake Shack, Microsoft","url":"https://stock-news.laohu8.com/highlight/detail?id=2479753661","media":"reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479753661?lang=en_us&edition=fundamental","pubTime":"2024-10-31 02:10","pubTimestamp":1730311852,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Shake Shack, MicrosoftEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslett","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"68f7f41e2939d9741892e91720b4afc0","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nL4N3M61KY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OXY","CAKE","CVNA","NI","NNE","V","COP","AMGN","DVA","LUMN","MSFT","ZBH","LLY","EXC","XOM","THRY","AMZN","HRMY","NVDA","HUM","CZR","OMCL","OKE","KHC","ANAB","AVGO","UIS","CAT","MRVL","QCOM","ABBV","HMST","WRK","DBX","FMC","BAC","CMG","TECH","WING","OTIS","GPN","CVX","GRMN","GEHC","TCS","GOOGL","XPO","BPMC"],"gpt_icon":1},{"id":"2479730305","title":"Harmony Biosciences Is Maintained at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2479730305","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479730305?lang=en_us&edition=fundamental","pubTime":"2024-10-31 01:41","pubTimestamp":1730310060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HRMY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2024 13:41 ET (17:41 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY"],"gpt_icon":0},{"id":"2479398027","title":"BUZZ-Harmony Biosciences slides after secondary offering unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=2479398027","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479398027?lang=en_us&edition=fundamental","pubTime":"2024-10-31 00:27","pubTimestamp":1730305621,"startTime":"0","endTime":"0","summary":"** Shares of Harmony Biosciences    slide 14.5% to $35.47 on Weds, more than erasing Tuesday's gain, after co launches secondary offering   ** HRMY shares on track for biggest daily pct decline since Oct 13, 2023, when they plunged 30%   ** Co focused on rare neurological diseases late Tues announced 8 mln share offering, with Marshman Fund Trust and Valor Equity Partners each offloading 4 mln shares ** Offering would cut Marshman's holdings to ~6.7 mln shares, or 11.7% stake, while Chicago-based PE firm Valor's ownership would go to ~7.2 mln shares, or 12.7% stake, per SEC prospectus filing ** On Tues, HRMY shares finished up 16.1% at $41.49 after co reported Q3 rev of $186 mln, up 16% y/y, and GAAP EPS of 79 cents, both topping consensus, per LSEG   ** With move on the session, shares up ~10% YTD. Stock closed at $19.71 a year ago   ** JP Morgan sole bookrunner for stock offering ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU1119994496.HKD","IE000M9KFDE8.USD","LU0208291251.USD","LU0234572021.USD","LU0211326839.USD","BK4581","IE00BKVL7J92.USD","LU0203345920.USD","IE00BYXW3230.USD","IE00BWXC8680.SGD","IE00B1BXHZ80.USD","LU0787776722.HKD","LU0211326755.USD","BK4504","BK4550","BK4585","LU0106831901.USD","IE00BLSP4452.SGD","LU0320765646.SGD","LU0417517546.SGD","LU1162221912.USD","IE00BKDWB100.SGD","IE00B3S45H60.SGD","IE00BLSP4239.USD","IE00BBT3K403.USD","LU1064131342.USD","LU0238689110.USD","LU0323591593.USD","HRMY","BK4207","LU0203347892.USD","IE00BHPRN162.USD","LU0211327993.USD","LU0320765489.SGD","BK4588","IE0034235188.USD","LU","LU0211331839.USD","LU0215105999.USD","IE00BZ1G4Q59.USD","LU0683600562.USD","LU0267386448.USD","IE00B1XK9C88.USD","LU0070302665.USD","LU0170899867.USD","BK4533","LU0496365809.HKD","BK4534","LU1032466523.USD"],"gpt_icon":0},{"id":"1189478133","title":"Stock Track | Harmony Biosciences Stock Plunges Despite Robust Q3 Performance and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1189478133","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189478133?lang=en_us&edition=fundamental","pubTime":"2024-10-30 21:34","pubTimestamp":1730295288,"startTime":"0","endTime":"0","summary":"Shares of Harmony Biosciences Holdings, Inc.  experienced a sharp sell-off on October 30, 2024, plummeting 10% despite the company reporting strong third-quarter financial results and providing promising updates on its robust pipeline progress.Harmony Biosciences reported a 16% year-over-year increase in net revenue for Q3 2024, reaching $186 million, fueled by continued demand for its narcolepsy treatment WAKIX. The company surpassed the $2 billion mark in cumulative net revenue for WAKIX in le","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["HRMY"],"gpt_icon":0},{"id":"2479026082","title":"Cantor Fitzgerald Sticks to Its Buy Rating for Harmony Biosciences Holdings (HRMY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2479026082","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479026082?lang=en_us&edition=fundamental","pubTime":"2024-10-30 20:48","pubTimestamp":1730292488,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Charles Duncan maintained a Buy rating on Harmony Biosciences Holdings (HRMY – Research Report) yesterday and set a price...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-its-buy-rating-for-harmony-biosciences-holdings-hrmy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-its-buy-rating-for-harmony-biosciences-holdings-hrmy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HRMY"],"gpt_icon":0},{"id":"1183845242","title":"Stock Track | Harmony Biosciences Holdings Pre-Market Plunge Despite Robust Pipeline Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=1183845242","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183845242?lang=en_us&edition=fundamental","pubTime":"2024-10-30 20:16","pubTimestamp":1730290595,"startTime":"0","endTime":"0","summary":"Harmony Biosciences Holdings, Inc.  experienced a pre-market plunge of 6.72% on October 30, 2024, despite providing positive updates on its financial performance and pipeline progress during its Q3 2024 earnings call.The biopharmaceutical company reported strong revenue growth for its narcolepsy treatment WAKIX, with net sales reaching $186 million in Q3 2024, surpassing $2 billion in cumulative net revenue since launch. HRMY reiterated its 2024 net revenue guidance of $700 million to $720 milli","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Harmony Biosciences Holdings Pre-Market Plunge Despite Robust Pipeline Updates","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["HRMY"],"gpt_icon":0},{"id":"2479205068","title":"Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), Chemed (CHE) and Incyte (INCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2479205068","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479205068?lang=en_us&edition=fundamental","pubTime":"2024-10-30 19:50","pubTimestamp":1730289056,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Harmony Biosciences Holdings (HRMY – Research Report...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-harmony-biosciences-holdings-hrmy-chemed-che-and-incyte-incy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-harmony-biosciences-holdings-hrmy-chemed-che-and-incyte-incy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4550","BK4007","BK4585","BK4532","INCY","BK4139","HCSG","IE00B64QTZ34.USD","BK4137","CHE","HRMY","BK4196","IE00BLDYK493.USD","BK4588"],"gpt_icon":0},{"id":"2479227548","title":"Harmony Biosciences Holdings Launches Secondary Common Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2479227548","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479227548?lang=en_us&edition=fundamental","pubTime":"2024-10-30 17:04","pubTimestamp":1730279046,"startTime":"0","endTime":"0","summary":"Harmony Biosciences Holdings  said late Tuesday that it launched an underwritten public offering of up to 8 million common shares by Marshman Fund Trust II and Valor IV Pharma Holdings.The selling shareholders also plan to grant the underwriters a 30-day option to buy up to an additional 1.2 million shares of common stock.The company said it is not offering any shares of common stock and will not receive any proceeds from the offering.Price: 40.74, Change: -0.75, Percent Change: -1.81","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HRMY","BK4007"],"gpt_icon":1},{"id":"2479475592","title":"Harmony Biosciences Holdings Inc (HRMY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2479475592","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479475592?lang=en_us&edition=fundamental","pubTime":"2024-10-30 15:06","pubTimestamp":1730272005,"startTime":"0","endTime":"0","summary":"Cumulative Net Revenue for WAKIX: Surpassed $2 billion since launch.2024 Net Revenue Guidance: $700 million to $720 million.Cash, Cash Equivalents, and Investments: $504.7 million as of September 30, 2024.Non-GAAP Adjusted Net Income: $59.6 million or $1.03 per diluted share for Q3 2024.Total Operating Expenses: $81.6 million for Q3 2024, a 29% increase from the prior year.Cash Generation from Operations: $70.5 million in Q3 2024.Average Number of Patients on WAKIX: Approximately 6,800 in Q3 2024.GuruFocus has detected 4 Warning Sign with CALX.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Harmony Biosciences Holdings Inc  has a robust late-stage pipeline with plans to launch one or more new products or indications each year over the next five years.The company is advancing its pitolisant next-gen programs, with pitolisant GR and HD formulations expected to expand the patient base and address unmet needs.Q: Could you provide more det","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VFCWA8R3tOdWWDBTyoTT0Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/e3360546644549f02875806e215553a9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VFCWA8R3tOdWWDBTyoTT0Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/e3360546644549f02875806e215553a9"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/harmony-biosciences-holdings-inc-hrmy-070645298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HRMY"],"gpt_icon":0},{"id":"2479324182","title":"Q3 2024 Harmony Biosciences Holdings Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2479324182","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479324182?lang=en_us&edition=fundamental","pubTime":"2024-10-30 14:26","pubTimestamp":1730269589,"startTime":"0","endTime":"0","summary":"Brennan Doyle; Head of IR; Harmony Biosciences Holdings Inc. Jeffrey Dayno; President, Chief Executive Officer, Director; Harmony Biosciences Holdings Inc. Jeffrey Dierks; Chief Commercial Officer; Harmony Biosciences Holdings Inc. Kumar Budur; Chief Scientific Officer; Harmony Biosciences Holdings Inc. Sandip Kapadia; Chief Financial Officer, Chief Administrative Officer; Harmony Biosciences Holdings Inc. Thank you, Brennan, and thanks everyone for joining our conference call today. Q3 was another quarter of strong momentum for the team at Harmony, driving significant revenue growth for WAKIX and advancing our late stage clinical development programs. At our successful Investor Day event earlier this month, we were excited to share new data and outlined a clear path to becoming the leading CNS company focused on developi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q3-2024-harmony-biosciences-holdings-062629583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HRMY"],"gpt_icon":0},{"id":"1170749695","title":"Stock Track | Harmony Biosciences Stock Plunges After-Hours on Profit Taking Despite Strong Q3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1170749695","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170749695?lang=en_us&edition=fundamental","pubTime":"2024-10-30 06:34","pubTimestamp":1730241295,"startTime":"0","endTime":"0","summary":"Shares of Harmony Biosciences Holdings, Inc.  plunged over 6% in after-hours trading on Sunday, despite the company reporting better-than-expected third-quarter results and reiterating its full-year outlook.The biopharmaceutical company's stock fell sharply after the closing bell, as investors appeared to be taking profits following the company's strong earnings report. Harmony's third-quarter net income increased 20% year-over-year to $46.1 million, or $0.79 per diluted share, surpassing analys","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["HRMY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.harmonybiosciences.com","stockEarnings":[{"period":"1week","weight":-0.0547},{"period":"1month","weight":-0.0704},{"period":"3month","weight":-0.0555},{"period":"6month","weight":0.1368},{"period":"1year","weight":0.3095},{"period":"ytd","weight":0.0217}],"compareEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0704},{"period":"6month","weight":0.1207},{"period":"1year","weight":0.3195},{"period":"ytd","weight":0.2483}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.079082},{"month":2,"riseRate":0.5,"avgChangeRate":0.008817},{"month":3,"riseRate":0.5,"avgChangeRate":-0.015849},{"month":4,"riseRate":0,"avgChangeRate":-0.069867},{"month":5,"riseRate":0.5,"avgChangeRate":0.020636},{"month":6,"riseRate":0.75,"avgChangeRate":0.011425},{"month":7,"riseRate":0.75,"avgChangeRate":0.023571},{"month":8,"riseRate":0.75,"avgChangeRate":0.062136},{"month":9,"riseRate":0.6,"avgChangeRate":0.022496},{"month":10,"riseRate":0.6,"avgChangeRate":-0.014983},{"month":11,"riseRate":0.8,"avgChangeRate":0.068972},{"month":12,"riseRate":0.5,"avgChangeRate":0.030001}],"exchange":"NASDAQ","name":"Harmony Biosciences Holdings, Inc.","nameEN":"Harmony Biosciences Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Harmony Biosciences Holdings, Inc.(HRMY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Harmony Biosciences Holdings, Inc.(HRMY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Harmony Biosciences Holdings, Inc.,HRMY,Harmony Biosciences Holdings, Inc.股票,Harmony Biosciences Holdings, Inc.股票老虎,Harmony Biosciences Holdings, Inc.股票老虎国际,Harmony Biosciences Holdings, Inc.行情,Harmony Biosciences Holdings, Inc.股票行情,Harmony Biosciences Holdings, Inc.股价,Harmony Biosciences Holdings, Inc.股市,Harmony Biosciences Holdings, Inc.股票价格,Harmony Biosciences Holdings, Inc.股票交易,Harmony Biosciences Holdings, Inc.股票购买,Harmony Biosciences Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Harmony Biosciences Holdings, Inc.(HRMY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Harmony Biosciences Holdings, Inc.(HRMY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction